Is Guardant Health, Inc. (GH) a good stock to buy?

Olyth's institutional analysis of GH reveals an Altman Z-Score of 1.72 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.98B most recent), help investors decide if GH fits their risk profile.

What is the current P/E ratio for GH?

As of the latest trading session, Guardant Health, Inc. (GH) has a trailing P/E ratio of -26.94.

Who is the CEO of Guardant Health, Inc.?

The current Chief Executive Officer of Guardant Health, Inc. is Helmy Eltoukhy.

What was GH's revenue for the last 5 years?

According to its latest income statements, Guardant Health, Inc. reported annual revenues of $0.98B (2025), $0.74B (2024), $0.56B (2023), $0.45B (2022), $0.37B (2021) respectively.

Does GH pay a dividend?

Guardant Health, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does GH have?

In its latest reporting period, Guardant Health, Inc. generated $-0.23B in Free Cash Flow against a total debt load of $1.68B.

What is the Price-to-Book (P/B) ratio of Guardant Health, Inc.?

The Price-to-Book (P/B) ratio for Guardant Health, Inc. (GH) is currently -112.93.

What is the Price-to-Sales (P/S) ratio of GH?

Based on trailing twelve-month data, Guardant Health, Inc. (GH) trades at a Price-to-Sales (P/S) ratio of 11.64.

What is Guardant Health, Inc.'s Return on Equity (ROE)?

Guardant Health, Inc. (GH) has a Return on Equity (ROE) of 164.85%, representing its profitability relative to shareholder equity.

GH

Guardant Health, Inc. · Healthcare

87.17

6.11%(−5.67)

Pre-Market

Last Updated: — ET

52W L: $36.3652W H: $120.74

GH NEWS

defenseworld.net

1d ago

Terilyn Monroe Sells 3,832 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ: GH - Get Free Report) insider Terilyn Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider owned 20,990 shares of the company's stock, valued

seekingalpha.com

3d ago

Guardant Health: Leveraging Liquid Biopsy Testing Momentum

Guardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing. GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth. Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH's revenue momentum and market outperformance.

defenseworld.net

4d ago

Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd’s 6th Largest Position

Capricorn Fund Managers Ltd boosted its holdings in shares of Guardant Health, Inc. (NASDAQ: GH) by 197.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,787 shares of the company's stock after acquiring an additional 71,587 shares

defenseworld.net

5d ago

Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of “Moderate Buy” from Analysts

Guardant Health, Inc. (NASDAQ: GH - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-two analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty have assigned a buy recommendation to the company. The

businesswire.com

Mar 30

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or into.

defenseworld.net

Mar 26

Connective Portfolio Management LLC Acquires Shares of 7,000 Guardant Health, Inc. $GH

Connective Portfolio Management LLC bought a new stake in Guardant Health, Inc. (NASDAQ: GH) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,000 shares of the company's stock, valued at approximately $715,000. Guardant Health accounts for about 1.3% of Connective

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

1,999

IPO Date

2018-10-04

Beta

1.65

Websiteguardanthealth.com↗

Insider Activity

Monroe Terilyn J.

officer: Chief People Officer

SELL

3,832 SH @ $92.68

2026-04-06

Saia John G.

officer: Chief Legal Officer

BUY

5,895 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

BUY

2,925 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

SELL

6,013 SH @ $91.15

2026-04-01

Saia John G.

officer: Chief Legal Officer

BUY

1,667 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

BUY

974 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

SELL

2,925 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

SELL

5,895 SH @ $0.00

2026-04-01

Monroe Terilyn J.

officer: Chief People Officer

SELL

3,832 SH @ $92.68

2026-04-06

Saia John G.

officer: Chief Legal Officer

BUY

5,895 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

BUY

2,925 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

SELL

6,013 SH @ $91.15

2026-04-01

Saia John G.

officer: Chief Legal Officer

BUY

1,667 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

BUY

974 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

SELL

2,925 SH @ $0.00

2026-04-01

Saia John G.

officer: Chief Legal Officer

SELL

5,895 SH @ $0.00

2026-04-01